Moderna's Revenue
- Moderna's annual revenue was $6.85B in fiscal year 2023. The annual revenue decreased -$12.42B from $19.26B (in 2022) to $6.85B (in 2023), representing a -64.45% year-over-year decline.
- Moderna's quarterly revenue was $1.86B in the quarter ending Sep 2024. The quarterly revenue increased $24.00M from $1.83B (in Q3: June 2023) to $1.86B (in Q3: June 2024), representing a 1.31% year-over-year growth.
- The highest annual revenue for Moderna was $19.26B in fiscal year 2022.
- The lowest annual revenue was $48.04M in fiscal year 2019.
- The average revenue was $6.35B.
- Revenue is the amount of money generated by a business from sales of its goods or services. Refer to our glossary for more details, examples, and formulas.
Over the past 10 years (2015 - 2024):
Learn more about Moderna's Revenue by Segment and Revenue by Region.
Check out competitors to Moderna in a side-by-side comparison.
Explore additional financial metrics for Moderna.
Definition of Revenue :
| 2016 | 101536000.00 |
|---|---|
| 2017 | 176974000.00 |
| 2018 | 122512000.00 |
| 2019 | 48036000.00 |
| 2020 | 274490000.00 |
| 2021 | 17736000000.00 |
| 2022 | 19263000000.00 |
| 2023 | 6848000000.00 |
| Mar 2017 | 35724000.00 |
|---|---|
| Jun 2017 | 35724000.00 |
| Sep 2017 | 42473000.00 |
| Dec 2017 | 88416000.00 |
| Mar 2018 | 27460000.00 |
| Jun 2018 | 25831000.00 |
| Sep 2018 | 36662000.00 |
| Dec 2018 | 32816000.00 |
| Mar 2019 | 14115000.00 |
| Jun 2019 | 10030000.00 |
| Sep 2019 | 13338000.00 |
| Dec 2019 | 10553000.00 |
| Mar 2020 | 4457000.00 |
| Jun 2020 | 28442000.00 |
| Sep 2020 | 12216000.00 |
| Dec 2020 | 229375000.00 |
| Mar 2021 | 1743000000.00 |
| Jun 2021 | 4215000000.00 |
| Sep 2021 | 4829000000.00 |
| Dec 2021 | 6949000000.00 |
| Mar 2022 | 5940000000.00 |
| Jun 2022 | 4566000000.00 |
| Sep 2022 | 3220000000.00 |
| Dec 2022 | 5084000000.00 |
| Mar 2023 | 1862000000.00 |
| Jun 2023 | 344000000.00 |
| Sep 2023 | 1831000000.00 |
| Dec 2023 | 2813000000.00 |
| Mar 2024 | 167000000.00 |
| Jun 2024 | 241000000.00 |
| Sep 2024 | 1855000000.00 |
2023
Moderna's annual revenue was $6.85B in fiscal year 2023.
Moderna's quarterly revenue was $1.86B(Q1: Mar 2023), $344.00M(Q2: Jun 2023), $1.83B(Q3: Sep 2023), $2.81B(Q4: Dec 2023) in fiscal year 2023.
2022
Moderna's annual revenue was $19.26B in fiscal year 2023.
Moderna's quarterly revenue was $5.94B(Q1: Mar 2022), $4.57B(Q2: Jun 2022), $3.22B(Q3: Sep 2022), $5.08B(Q4: Dec 2022) in fiscal year 2022.
2021
Moderna's annual revenue was $17.74B in fiscal year 2023.
Moderna's quarterly revenue was $1.74B(Q1: Mar 2021), $4.22B(Q2: Jun 2021), $4.83B(Q3: Sep 2021), $6.95B(Q4: Dec 2021) in fiscal year 2021.
2020
Moderna's annual revenue was $274.49M in fiscal year 2023.
Moderna's quarterly revenue was $4.46M(Q1: Mar 2020), $28.44M(Q2: Jun 2020), $12.22M(Q3: Sep 2020), $229.38M(Q4: Dec 2020) in fiscal year 2020.
2019
Moderna's annual revenue was $48.04M in fiscal year 2023.
Moderna's quarterly revenue was $14.12M(Q1: Mar 2019), $10.03M(Q2: Jun 2019), $13.34M(Q3: Sep 2019), $10.55M(Q4: Dec 2019) in fiscal year 2019.
2018
Moderna's annual revenue was $122.51M in fiscal year 2023.
Moderna's quarterly revenue was $27.46M(Q1: Mar 2018), $25.83M(Q2: Jun 2018), $36.66M(Q3: Sep 2018), $32.82M(Q4: Dec 2018) in fiscal year 2018.
2017
Moderna's annual revenue was $176.97M in fiscal year 2023.
Moderna's quarterly revenue was $35.72M(Q1: Mar 2017), $35.72M(Q2: Jun 2017), $42.47M(Q3: Sep 2017), $88.42M(Q4: Dec 2017) in fiscal year 2017.
2016
Moderna's annual revenue was $101.54M in fiscal year 2023.
in fiscal year 2016.
| 2016 | 0 |
|---|---|
| 2017 | +74.30 |
| 2018 | -30.77 |
| 2019 | -60.79 |
| 2020 | +471.43 |
| 2021 | +6,361.44 |
| 2022 | +8.61 |
| 2023 | -64.45 |
| Q1: Mar 17 | 0 |
|---|---|
| Q2: Jun 17 | 0 |
| Q3: Sep 17 | 0 |
| Q4: Dec 17 | 0 |
| Q1: Mar 18 | -23.13 |
| Q2: Jun 18 | -27.69 |
| Q3: Sep 18 | -13.68 |
| Q4: Dec 18 | -62.88 |
| Q1: Mar 19 | -48.60 |
| Q2: Jun 19 | -61.17 |
| Q3: Sep 19 | -63.62 |
| Q4: Dec 19 | -67.84 |
| Q1: Mar 20 | -68.42 |
| Q2: Jun 20 | 183.57 |
| Q3: Sep 20 | -8.41 |
| Q4: Dec 20 | 2,073.55 |
| Q1: Mar 21 | 39,007.02 |
| Q2: Jun 21 | 14,719.63 |
| Q3: Sep 21 | 39,430.12 |
| Q4: Dec 21 | 2,929.54 |
| Q1: Mar 22 | 240.79 |
| Q2: Jun 22 | 8.33 |
| Q3: Sep 22 | -33.32 |
| Q4: Dec 22 | -26.84 |
| Q1: Mar 23 | -68.65 |
| Q2: Jun 23 | -92.47 |
| Q3: Sep 23 | -43.14 |
| Q4: Dec 23 | -44.67 |
| Q1: Mar 24 | -91.03 |
| Q2: Jun 24 | -29.94 |
| Q3: Sep 24 | 1.31 |
2023
Moderna’s annual revenue decreased -64.45% during fiscal year 2023 compared to 2022. It represents a decline of -$12.42B from $19.26B (in 2022) to $6.85B (in 2023).
2022
Moderna’s annual revenue increased +8.61% during fiscal year 2022 compared to 2021. It represents a growth of $1.53B from $17.74B (in 2021) to $19.26B (in 2022).
2021
Moderna’s annual revenue decreased +6,361.44% during fiscal year 2021 compared to 2020. It represents a decline of $17.46B from $274.49M (in 2020) to $17.74B (in 2021).
2020
Moderna’s annual revenue increased +471.43% during fiscal year 2020 compared to 2019. It represents a growth of $226.45M from $48.04M (in 2019) to $274.49M (in 2020).
2019
Moderna’s annual revenue decreased -60.79% during fiscal year 2019 compared to 2018. It represents a decline of -$74.48M from $122.51M (in 2018) to $48.04M (in 2019).
2018
Moderna’s annual revenue decreased -30.77% during fiscal year 2018 compared to 2017. It represents a decline of -$54.46M from $176.97M (in 2017) to $122.51M (in 2018).
2017
Moderna’s annual revenue increased +74.30% during fiscal year 2017 compared to 2016. It represents a growth of $75.44M from $101.54M (in 2016) to $176.97M (in 2017).
Summary Table (Annual)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| 2023 | $6.85B | -64.45% |
| 2022 | $19.26B | +8.61% |
| 2021 | $17.74B | +6,361.44% |
| 2020 | $274.49M | +471.43% |
| 2019 | $48.04M | -60.79% |
| 2018 | $122.51M | -30.77% |
| 2017 | $176.97M | +74.30% |
Summary Table (Quarterly)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| Q3: Sep 24 | $1.86B | 1.31% |
| Q2: Jun 24 | $241.00M | -29.94% |
| Q1: Mar 24 | $167.00M | -91.03% |
| Q4: Dec 23 | $2.81B | -44.67% |
| Q3: Sep 23 | $1.83B | -43.14% |
| Q2: Jun 23 | $344.00M | -92.47% |
| Q1: Mar 23 | $1.86B | -68.65% |
| Q4: Dec 22 | $5.08B | -26.84% |
| Q3: Sep 22 | $3.22B | -33.32% |
| Q2: Jun 22 | $4.57B | 8.33% |
| Q1: Mar 22 | $5.94B | 240.79% |
| Q4: Dec 21 | $6.95B | 2,929.54% |
| Q3: Sep 21 | $4.83B | 39,430.12% |
| Q2: Jun 21 | $4.22B | 14,719.63% |
| Q1: Mar 21 | $1.74B | 39,007.02% |
| Q4: Dec 20 | $229.38M | 2,073.55% |
| Q3: Sep 20 | $12.22M | -8.41% |
| Q2: Jun 20 | $28.44M | 183.57% |
| Q1: Mar 20 | $4.46M | -68.42% |
| Q4: Dec 19 | $10.55M | -67.84% |
| Q3: Sep 19 | $13.34M | -63.62% |
| Q2: Jun 19 | $10.03M | -61.17% |
| Q1: Mar 19 | $14.12M | -48.60% |
| Q4: Dec 18 | $32.82M | -62.88% |
| Q3: Sep 18 | $36.66M | -13.68% |
| Q2: Jun 18 | $25.83M | -27.69% |
| Q1: Mar 18 | $27.46M | -23.13% |
| Q4: Dec 17 | $88.42M | 0% |
| Q3: Sep 17 | $42.47M | 0% |
| Q2: Jun 17 | $35.72M | 0% |
| Q1: Mar 17 | $35.72M | 0% |
Related company
Related
-
Agilent Technologies Revenue
-
Eli Lilly and Company Revenue
-
Stryker Corporation Revenue
-
Johnson & Johnson Revenue
-
AbbVie Revenue
-
Merck & Co. Revenue
-
Thermo Fisher Scientific Revenue
-
Abbott Laboratories Revenue
-
Danaher Corporation Revenue
-
Amgen Revenue
-
Pfizer Revenue
-
Boston Scientific Corporation Revenue
-
Bristol-Myers Squibb Company Revenue
-
Cigna Corporation Revenue
-
McKesson Corporation Revenue
-
Cardinal Health Revenue
